Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
1.160
-0.360 (-23.68%)
At close: Mar 28, 2025, 4:00 PM
1.100
-0.060 (-5.17%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Plus Therapeutics Employees
Plus Therapeutics had 20 employees as of December 31, 2023. The number of employees increased by 3 or 17.65% compared to the previous year.
Employees
20
Change (1Y)
3
Growth (1Y)
17.65%
Revenue / Employee
$291,200
Profits / Employee
-$648,900
Market Cap
39.37M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PSTV News
- 3 days ago - Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 10 days ago - Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate - GlobeNewsWire
- 11 days ago - Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025 - GlobeNewsWire
- 19 days ago - D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement - Accesswire
- 20 days ago - Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement - GlobeNewsWire
- 23 days ago - Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma - GlobeNewsWire
- 24 days ago - Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer - GlobeNewsWire